Vireo Growth (VREOF) Total Debt Growth (1y) (2021 - 2026)
Vireo Growth (VREOF) Total Debt Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -3.69% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 37.49% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -2.48% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 4.38% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -6.91% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 41.53% |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | 174.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 217.23% |
| Dec 31, 2025 | 127.69% |
| Sep 30, 2025 | 154.06% |
| Jun 30, 2025 | 73.57% |
| Mar 31, 2025 | 2.80% |
| Dec 31, 2024 | -47.53% |
| Sep 30, 2024 | -2.55% |
| Jun 30, 2024 | 8.40% |
| Mar 31, 2024 | 4.62% |
| Dec 31, 2023 | 107.55% |
| Sep 30, 2023 | 6.95% |
| Jun 30, 2023 | 26.00% |
| Mar 31, 2023 | 86.49% |
| Dec 31, 2022 | 112.33% |
| Sep 30, 2022 | 157.17% |
| Jun 30, 2022 | 133.40% |
| Mar 31, 2022 | 66.40% |
| Dec 31, 2021 | 1,131.08% |